These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32344313)

  • 1. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
    Carboni E; Carta AR; Carboni E
    Med Hypotheses; 2020 Jul; 140():109776. PubMed ID: 32344313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of diabetic patients infected by the SARS-CoV-2.
    Elamari S; Motaib I; Zbiri S; Elaidaoui K; Chadli A; Elkettani C
    Pan Afr Med J; 2020; 37():32. PubMed ID: 33209159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of COVID-19: Changes in laboratory parameters.
    Lagadinou M; Salomou EE; Zareifopoulos N; Marangos M; Gogos C; Velissaris D
    Infez Med; 2020 Jun; 28(suppl 1):89-95. PubMed ID: 32532944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Role of Oxygen-Ozone Therapy in Treatment of COVID-19 Pneumonia.
    Hernández A; Viñals M; Isidoro T; Vilás F
    Am J Case Rep; 2020 Aug; 21():e925849. PubMed ID: 32804917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort.
    Ayanian S; Reyes J; Lynn L; Teufel K
    Biomark Med; 2020 Aug; 14(12):1091-1097. PubMed ID: 32677844
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-6-based mortality risk model for hospitalized patients with COVID-19.
    Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E
    J Allergy Clin Immunol; 2020 Oct; 146(4):799-807.e9. PubMed ID: 32710975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
    Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study.
    Pan F; Yang L; Li Y; Liang B; Li L; Ye T; Li L; Liu D; Gui S; Hu Y; Zheng C
    Int J Med Sci; 2020; 17(9):1281-1292. PubMed ID: 32547323
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.
    Figliozzi S; Masci PG; Ahmadi N; Tondi L; Koutli E; Aimo A; Stamatelopoulos K; Dimopoulos MA; Caforio ALP; Georgiopoulos G
    Eur J Clin Invest; 2020 Oct; 50(10):e13362. PubMed ID: 32726868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
    Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P
    Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis.
    Ghahramani S; Tabrizi R; Lankarani KB; Kashani SMA; Rezaei S; Zeidi N; Akbari M; Heydari ST; Akbari H; Nowrouzi-Sohrabi P; Ahmadizar F
    Eur J Med Res; 2020 Aug; 25(1):30. PubMed ID: 32746929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical course of coronavirus disease-2019 in pregnancy.
    Pereira A; Cruz-Melguizo S; Adrien M; Fuentes L; Marin E; Perez-Medina T
    Acta Obstet Gynecol Scand; 2020 Jul; 99(7):839-847. PubMed ID: 32441332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.